US 12,275,738 B2
CDK9 inhibitors
Hariprasad Vankayalapati, Sandy, UT (US); Zhaoliang Li, Salt Lake City, UT (US); Kyle Medley, American Fork, UT (US); Dongqing Yan, Salt Lake City, UT (US); and David J. Bearss, Alpine, UT (US)
Assigned to Biolexis Therapeutics, Inc., Lehi, UT (US)
Filed by Biolexis Therapeutics, Inc., Lehi, UT (US)
Filed on Apr. 6, 2023, as Appl. No. 18/296,930.
Claims priority of provisional application 63/329,105, filed on Apr. 8, 2022.
Prior Publication US 2023/0322792 A1, Oct. 12, 2023
Int. Cl. C07D 487/04 (2006.01); A61P 35/00 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 35/00 (2018.01)] 19 Claims
 
1. A compound having the following Structure (I):

OG Complex Work Unit Chemistry
or a stereoisomer or salt thereof, wherein:
R1 is hydrogen, halo, hydroxy, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl;
R2 is hydrogen, halo, hydroxy, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl;
R3 is 5-6 membered heterocyclyl;
each occurrence of R4 and R5 are independently halo, hydroxy, cyano, amino, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl;
m is 0, 1, or 2;
n is 0, 1, 2, 3, or 4; and
p is 0, 1, or 2,
wherein each R1, R2, R3, R4, and R5 is optionally substituted with one or more substituents.